No Data
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
Stifel Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $80
Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)